QUIDELORTHO CORP

QuidelOrtho CFO’s 356k‑RSU grant signals long‑term confidence, offering growth‑aligned rewards amid a challenging stock rally and a 29% monthly upside.

QuidelOrtho insider buying shows confidence; EVP’s buy‑sell‑buy RSU pattern hints at a bullish outlook amid volatility.

QuidelOrtho insider trading shows CEO Blaser’s confidence in future diagnostics and a disciplined capital strategy that signals potential upside for long‑term investors.

Insider buy: QuidelOrtho’s Chief Legal Officer purchases 73k shares amid market dip, signaling confidence in LEX Diagnostics acquisition and future upside.

QuidelOrtho CFO Busky’s recent share purchase signals confidence amid a steep decline—showing insider optimism and potential upside for investors.

Insider buying at QuidelOrtho signals confidence amid a steep decline. Discover what the CEO, CFO, and executives’ recent purchases mean for investors.

Insider buying fuels optimism for QuidelOrtho stock: CFO Busky’s purchase signals confidence despite recent dips and mixed insider activity, offering a cautious upside bet for investors.

CEO Blaser’s recent insider buying of QuidelOrtho stock amid a 41% year‑to‑date decline signals long‑term confidence, but investors should weigh this bullish cue against the company’s guidance, valuation and competitive pressures in diagnostics.

Bowman Lee’s RSU and NSO grants at QuidelOrtho signal executive optimism amid earnings pressure, offering investors insight into future value creation.

Insider buys at QuidelOrtho signal confidence in its R&D pipeline, highlighting leadership’s equity strategy amid a challenging market and negative earnings.